- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 167 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 398 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 179 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 197 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.08.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue | 87 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with... ► Artikel lesen | |
| 07.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the second quarter 2025 | 383 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 7 August 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the second quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 06.08.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | 404 | Xetra Newsboard | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| 01.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKD-related anemia | 344 | GlobeNewswire (Europe) | Stockholm, Sweden - 1 August 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that dose levels for Part 2 of its ongoing Phase IIa clinical study of sevuparin in patients with chronic... ► Artikel lesen | |
| 29.07.25 | Modus Therapeutics Holding AB: Extraordinary General Meeting in Modus Therapeutics Holding AB (publ) | 196 | GlobeNewswire (Europe) | Modus Therapeutics' Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
To amend the company's articles of association in order to increase the limits of the company's... ► Artikel lesen | |
| 14.07.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 350 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
| 08.07.25 | Modus Therapeutics Holding AB: Modus Therapeutics completes enrollment in Part 1 of the Phase IIa sevuparin study in chronic kidney disease with anemia | 239 | GlobeNewswire (Europe) | Stockholm, Sweden - 8 July 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment... ► Artikel lesen | |
| 27.06.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 49 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units... ► Artikel lesen | |
| 14.05.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the first quarter 2025 | 517 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 14 May 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the first quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 02.04.25 | Modus Therapeutics Holding AB: Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study | 195 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - April 2, 2025: Modus Therapeutics Holding AB ("Modus"), a company developing innovative treatments for patients with significant unmet medical needs, today announced the opening... ► Artikel lesen | |
| 20.02.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2024 | 195 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 20 February 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,535 | +2,68 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| MARINOMED BIOTECH | 17,100 | -0,29 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,068 | +5,96 % | ESGFIRE Commentary - Replenish Nutrients Announces Up to $3M Private Placement to Accelerate Growth | ||
| SANA BIOTECHNOLOGY | 3,930 | +10,70 % | Sana Biotechnology, Inc. - 8-K, Current Report | ||
| NOVABRIDGE BIOSCIENCES | 2,800 | -10,83 % | NovaBridge Biosciences - 6-K, Report of foreign issuer | ||
| GENEURO | 0,032 | -100,00 % | GeNeuro SA Announces the End of the Debt Moratorium and the Commencement of Bankruptcy Proceedings | Regulatory News:
GeNeuro SA (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announces that the Geneva... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Umsatz und Ergebnis des vierten Quartals hätten die Erwartungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns |
Das Unternehmen MODUS THERAPEUTICS HOLDING AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,000 (+1,28 %) liegt der Kurs bei 0,016 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.